Memory NK Cell Expansion Using Preactivation and Vesicle Mediators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding natural killer (NK) cells are limited by their inability to achieve therapeutic doses, are costly, and often result in significant toxicity and short persistence of NK cells in patients.
Innovation Solution
The method involves preactivating NK cells with stimulatory cytokines such as IL-12, IL-15, and IL-18, followed by expansion using vesicles containing NK cell effector agents like PM21 particles, EX21 exosomes, or FC21 feeder cells, without the need for live feeder cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional NK cell expansion methods are used, then NK cell numbers increase, but the expansion is limited and cannot achieve therapeutic doses
Solution Approach 1:
The patent applies preliminary action by pre-activating NK cells with stimulatory cytokines (IL-12, IL-15, IL-18) before expansion. This pre-activation step primes the NK cells to be in a more responsive state, enabling them to proliferate more efficiently when exposed to the vesicle-containing effector agents, thereby overcoming the limitation of conventional methods that cannot achieve sufficient expansion levels
Solution Approach 2:
The patent uses vesicles containing NK cell effector agents as intermediaries to mediate the expansion process. These vesicles deliver critical signals to the pre-activated NK cells, enabling controlled and efficient proliferation without requiring direct cell-to-cell contact or live feeder cells, thus achieving therapeutic-level expansion
2Quantity of substance
If conventional NK cell expansion methods are used, then NK cells are produced, but the process is costly
Solution Approach 1:
The patent extracts the essential function of live feeder cells by isolating and purifying NK cell effector agents into vesicles. This extraction eliminates the need for complex live cell cultures and feeder cell systems, significantly simplifying the manufacturing process and reducing costs while maintaining effective NK cell expansion
Solution Approach 2:
The patent employs vesicles as disposable carriers containing effector agents. These vesicles can be produced in advance, stored, and used in a controlled manner for each expansion batch, replacing expensive and complex live feeder cell systems with a more economical and scalable approach
3Quantity of substance
If conventional NK cell expansion methods are used, then NK cells are produced, but significant toxicity occurs
Solution Approach 1:
The vesicles act as intermediaries that deliver effector agents in a controlled and targeted manner to NK cells. This mediated delivery system avoids the uncontrolled paracrine signaling and potential toxic effects associated with conventional methods that use high concentrations of cytokines or direct cell-cell contact, thereby reducing toxicity while achieving effective expansion
4Quantity of substance
If conventional NK cell expansion methods are used, then NK cells are produced, but persistence in patients is short
Solution Approach 1:
The pre-activation step with stimulatory cytokines before expansion primes the NK cells to develop enhanced functional properties and persistence capabilities. This preliminary conditioning ensures that the expanded NK cells are not only numerous but also have improved survival and persistence characteristics when infused into patients
Solution Approach 2:
The patent changes the functional parameters of NK cells through pre-activation and controlled expansion using vesicles. This process induces phenotypic and functional changes that enhance the persistence of NK cells in vivo, transforming them from short-lived effector cells to more persistent therapeutic agents
Data Source
AI summary
Disclosed are compositions and methods relating to the expansion of memory NK cells.